Rarity Bioscience New office

WE GROW – Moving to new HQ

Amidst the vibrant ambiance of Uppsala Science Park, on the evening of April 10th, a gathering of over a hundred investors, industrialists, customers, and esteemed guests from the life science community congregated to mark this significant milestone in Rarity Bioscience’s journey. 

Rarity Bioscience's Shift to Uppsala Science Park

Having outgrown its previous premises at BMC Uppsala University, Rarity Bioscience’s relocation to Uppsala Science Park signifies a strategic transition towards commercial focus and with it also a build-out of the production facility. 

"It's truly fantastic to stand here today and see how dreams and innovation are now taking shape and becoming available to both research groups and hospitals. We strongly hope that this can improve the patients' journey with the right treatment at the right time and towards recovery."

Innovating Precision Medicine

With a focus on overcoming barriers such as high costs and low sensitivity in diagnostic tests, Rarity Bioscience is committed to democratizing ultra-sensitive mutation detection, enhancing clinical decision-making, and ultimately improving patient outcomes. 

Central to this endeavour is the new superRCA technology. Rarity Bioscience can now offer its customers the increased sensitivity they demand, while avoiding the need for expensive capital investments as it runs on already available lab equipment. 

Read more about our technology

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »